System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Epublish

PubMed: 39733019 DOI: 10.1038/s41598-024-83288-5

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.

Sci Rep 14(1):31492

Authors: Aitor Villate, Maitane Olivares, Aresatz Usobiaga, Paula Unzueta-Larrinaga, Rocío Barrena-Barbadillo, Luis Felipe Callado, Nestor Etxebarria, Leyre Urigüen

Affiliations

  • Department of Analytical Chemistry, University of the Basque Country, UPV/EHU, Leioa, Bizkaia, Spain.
  • PiE-UPV/EHU. Plentzia Itsas Estazioa, Areatza Pasealekua, 48620, Plentzia , (Biscay), Basque Country, Spain.
  • Department of Pharmacology, University of the Basque Country, UPV/EHU, Sarriena S/N, 48940, Leioa, Bizkaia, Spain.
  • BioBizkaia Health Research Institute, Bizkaia, Spain.
  • Department of Nursing, University of the Basque Country, UPV/EHU, Leioa, Bizkaia, Spain.
  • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
  • Department of Pharmacology, University of the Basque Country, UPV/EHU, Sarriena S/N, 48940, Leioa, Bizkaia, Spain.
  • BioBizkaia Health Research Institute, Bizkaia, Spain.
  • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.

Abstract

Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the metabolic underpinnings of cannabis abuse and schizophrenia development. The use of liquid chromatography-high resolution mass spectrometry enabled the annotation of 119 metabolites, with the highest identification confidence level achieved for 16 compounds. Notably, a marked reduction in acylcarnitines, including octanoylcarnitine and decanoylcarnitine, was observed across all patient groups compared to controls. In cannabis use disorder patients, N-acyl amino acids (NAAAs), particularly N-palmitoyl threonine and N-palmitoyl serine, showed a strong downregulation, a pattern also seen in schizophrenia and dual diagnosis patients. Conversely, elevated levels of 7-dehydrodesmosterol were detected in schizophrenia and dual diagnosis patients relative to controls. These findings suggest a potential link between metabolic disruptions and the pathophysiology of both disorders. The untargeted lipidomics approach offers a powerful tool to identify novel biomarkers, enhancing our understanding of the biological relationship between cannabis abuse and schizophrenia, and paving the way for future therapeutic strategies targeting metabolic pathways in these conditions.

MeSH

Biomarkers, Schizophrenia, Diagnosis, Lipidomics, Plasma, Diagnosis, Dual (Psychiatry)